Elite in Non-Small Cell Lung Cancer (NSCLC)

Dr. Patrick M. Forde

Hematology Oncology | Oncology

401 North Broadway, Weinberg Bdg.,

Baltimore, MD

Clinical Trials:Currently Recruiting for 2 Trials

Accepting New Patients

Elite in Non-Small Cell Lung Cancer (NSCLC)

401 North Broadway, Weinberg Bdg.,

Baltimore, MD

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Patrick Forde is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Forde is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, and Small Cell Lung Cancer (SCLC). Dr. Forde is currently accepting new patients.

His clinical research consists of co-authoring 180 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 98 articles and participated in 9 clinical trials in the study of Non-Small Cell Lung Cancer (NSCLC).

Specialties

Hematology Oncology

Oncology

Licenses

Internal Medicine in MD

Languages Spoken

English

Irish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

CareFirst

Cigna

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Highmark

Humana

HMO
INDEMNITY
POS
PPO

Johns Hopkins Healthcare

HMO
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE-MEDICAID PLAN

Medicaid

OTHER MEDICAID
STATE MEDICAID

UnitedHealthcare

Walgreens

MEDICARE DISCOUNT CARD
MEDICARE PDP
OTHER MEDICARE

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 6 Less Insurance Carriers -

Locations

401 North Broadway, Weinberg Bdg., Baltimore, MD 21231

Call: 410-955-3974

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Enrollment Status: Recruiting

Publish Date: October 15, 2025

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium

Study Phase: Phase 3

Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Enrollment Status: Recruiting

Publish Date: October 14, 2025

Intervention Type: Procedure, Drug

Study Phase: Phase 2

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Enrollment Status: Active_not_recruiting

Publish Date: October 06, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Phase: Not Applicable

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Drug

Study Drug: Erlotinib Hydrochloride

Study Phase: Phase 3

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.

Enrollment Status: Active_not_recruiting

Publish Date: August 15, 2025

Intervention Type: Drug

Study Drug: Nivolumab

Study Phase: Phase 2

DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial

Enrollment Status: Completed

Publish Date: July 18, 2025

Intervention Type: Drug

Study Drug: Durvalumab

Study Phase: Phase 3

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Enrollment Status: Active_not_recruiting

Publish Date: June 26, 2025

Intervention Type: Drug

Study Drugs: Nivolumab, Ipilimumab

Study Phase: Phase 2

A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Enrollment Status: Completed

Publish Date: June 13, 2025

Intervention Type: Biological, Drug

Study Drugs: LGK974, PDR001

Study Phase: Phase 1

Preoperative Immune Checkpoint Inhibitor Therapy for Patients With Primary Untreated or Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN)

Enrollment Status: Completed

Publish Date: November 21, 2024

Intervention Type: Drug

Study Drug: Nivolumab

Study Phase: Phase 2

Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and Pembrolizumab (MK-3475) Compared to Pembrolizumab Alone for Mesothelin-Positive Malignant Pleural Mesothelioma

Enrollment Status: Active_not_recruiting

Publish Date: October 16, 2024

Intervention Type: Biological, Other

Study Drugs: Anetumab Ravtansine, Pembrolizumab

Study Phase: Phase 1/Phase 2

Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies

Enrollment Status: Terminated

Publish Date: December 06, 2023

Intervention Type: Drug

Study Drugs: MBG453, PDR001, Decitabine

Study Phase: Phase 1/Phase 2

Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma

Enrollment Status: Completed

Publish Date: July 05, 2023

Intervention Type: Drug

Study Drug: Durvalumab

Study Phase: Phase 2

Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)

Enrollment Status: Completed

Publish Date: January 11, 2023

Intervention Type: Drug, Biological

Study Drugs: PDR001, LCL161, Everolimus, Panobinostat, QBM076, HDM201

Study Phase: Phase 1

Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies

Enrollment Status: Completed

Publish Date: August 03, 2022

Intervention Type: Biological

Study Phase: Phase 1/Phase 2

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers

Enrollment Status: Completed

Publish Date: August 30, 2021

Intervention Type: Drug

Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab

Study Phase: Phase 1

Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure

Enrollment Status: Terminated

Publish Date: August 28, 2019

Intervention Type: Drug

Study Phase: Phase 2

View 15 Less Clinical Trials

180 Total Publications

Macrophage CCL18 Promotes Lung Inflammation in Checkpoint Inhibitor Pneumonitis.

Journal: American journal of respiratory cell and molecular biology

Published: October 10, 2025

View All 180 Publications

Similar Doctors

Elite in Non-Small Cell Lung Cancer (NSCLC)

Dr. Julie R. Brahmer

Oncology

Elite in Non-Small Cell Lung Cancer (NSCLC)

Dr. Julie R. Brahmer

Oncology

Johns Hopkins University

301 Mason Lord Dr, Suite 1201,

Baltimore, MD

(2.6 miles away)

410-550-2339

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Julie Brahmer is an Oncologist in Baltimore, Maryland. Dr. Brahmer is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Brahmer is currently accepting new patients.

Elite in Non-Small Cell Lung Cancer (NSCLC)

Dr. Taofeek K. Owonikoko

Hematology Oncology | Hematology | Oncology

Elite in Non-Small Cell Lung Cancer (NSCLC)

Dr. Taofeek K. Owonikoko

Hematology Oncology | Hematology | Oncology

University Of Maryland Oncology Associates PA

22 S Green St,

Baltimore, MD

(1.7 miles away)

410-328-1230

Languages Spoken:

English, German, Spanish, Yoruba

See accepted insurances

Accepting New Patients

Taofeek Owonikoko is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Owonikoko is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Owonikoko is currently accepting new patients.

Elite in Non-Small Cell Lung Cancer (NSCLC)

Dr. Josephine L. Feliciano

Hematology Oncology | Hematology | Oncology

Elite in Non-Small Cell Lung Cancer (NSCLC)

Dr. Josephine L. Feliciano

Hematology Oncology | Hematology | Oncology

Johns Hopkins University

4940 Eastern Ave,

Baltimore, MD

(2.6 miles away)

410-550-0100

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Josephine Feliciano is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Feliciano is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Feliciano is currently accepting new patients.

VIEW MORE NON-SMALL CELL LUNG CANCER (NSCLC) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Forde's expertise for a condition

ConditionClose